Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
Acase of diffuse scleroderma in a 56-year-old woman who received paclitaxel for the treatment of a metastatic ovarian cancer is presented. The clinical cutaneous alterations, as well as the capillaroscopic and histological findings, were indistinguishable from those encountered in definite systemic sclerosis (SSc). In contrast to SSc, Raynaud's phenomenon and cutaneous calcinosis were absent and antinuclear antibodies were negative. The temporal relationship between the onset of skin involvement and administration of the drug may indicate an effect of paclitaxel.
De Angelis
R
R
Ospedale Augusto Murri, via dei Colli 52, 60035 Jesi, Ancona, Italy. deaross65@libero.it
Bugatti
L
L
Cerioni
A
A
Del Medico
P
P
Filosa
G
G
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002196:Capillaries / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects*; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000473:pathology; D012867:Skin / Q000098:blood supply
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel